Simultaneous determination of simvastatin, lovastatin and niacin in human plasma by LC-MS/MS and its application to a human pharmacokinetic study

Biomedical Chromatography

Volumn 26, Issue 4, 2012, Pages 476-484

  Pilli, Nageswara Rao ^a   Mullangi, Ramesh ^b   Inamadugu, Jaswanth Kuamr ^c   Nallapati, Indira Kumari ^d   Rao, Seshagiri ^e  

^a JNTUH COLLEGE OF ENGINEERING   (India)

^b JUBILANT BIOSYS LTD   (India)

^c SRI VENKATESWARA UNIVERSITY   (India)

^d ANDHRA MEDICAL COLLEGE   (India)

^e ANDHRA UNIVERSITY   (India)

Author keywords

Human plasma; LC MS MS; Lovastatin; Niacin; Pharmacokinetics; Quantification; Simvastatin

Indexed keywords

CARBOXYLIC ACIDS; PLASMA (HUMAN); POSITIVE IONS; PYRIDINE;

HUMAN PLASMAS; INTERNAL STANDARDS; LC-MS-MS; LC.MS/MS; LOVASTATIN; NIACIN; QUANTIFICATION; SIMPLE++; SIMULTANEOUS DETERMINATIONS; SIMVASTATIN;

PHARMACOKINETICS;

ACETIC ACID ETHYL ESTER; ACETONITRILE; AMMONIUM ACETATE; MEVINOLIN; NEVIRAPINE; NICOTINIC ACID; SIMVASTATIN;

ADULT; AREA UNDER THE CURVE; ARTICLE; CHEMICAL STRUCTURE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG HALF LIFE; DRUG RETENTION; DRUG STABILITY; FLOW RATE; HUMAN; LIMIT OF QUANTITATION; LIQUID CHROMATOGRAPHY; LIQUID LIQUID EXTRACTION; MALE; MASS SPECTROMETRY; NORMAL HUMAN; PH; PHARMACOKINETICS; PLASMA CONCENTRATION-TIME CURVE;

EID: 84858008850     PISSN: 02693879     EISSN: 10990801     Source Type: Journal    
DOI: 10.1002/bmc.1690     Document Type: Article

References (22)

1. Cannon CP, Braunwald E, McCabe CH, Rader DJ, Rouleau JL Belder R, Joyal SV, Hill KA, Pfeffer MA and Skene AM. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. The New England Journal of Medicine 2004; 350: 1495-1504.
2. Chi J, Jayewardene AL, Stone JA and Aweeka FT. An LC-MS-MS method for the determination of nevirapine, a non-nucleoside reverse transcriptase inhibitor, in human plasma. Journal of Pharmaceutical and Biomedical Analysis 2003; 31: 953-959.
3. Corsini A, Bellosta S, Baetta R, Fumagalli R, Paoletti R and Bernini F. New insights into the pharmocodynamic and pharmacokinetic properties of statins. Phrmacology and Therapeutics 1999; 84: 413-428.
4. Davidson MH. Niacin and statin combination therapy: balancing HDL and LDL to reduce cardiovascular risk. Cardiology Forum Report Released in December 2007.
5. Davidson MH and Toth PP. Comparative effects of lipid-lowering therapies. Progress in Cardiovascular Diseases 2004; 47: 73-104.
6. Delemos JA, Blazing MA and Wiviott SD, Lewis EF, Fox KAA, White HD, Rouleau J-L, Pedersen TR, Gardner LH, Mukherjee R, Ramsey KE, Palmisano J, Bilheimer DW, Pfeffer MA, Califf RM and Braunwald E. Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z study. JAMA 2004; 292: 1307-1316.
7. Guyton JR. Combination drug therapy for combined hyperlipidemia. Current Cardiology Reports 1999; 1: 244-250.
8. Henwood JM and Heel RC. Lovastatin. A preliminary review of its pharmacodynamic properties and therapeutic use in hyperlipidaemia. Drugs 1988; 36: 429-454.
9. Inamadugu JK, Darmaramadugu R, Mullangi R and Ponneri V. Simultaneous determination of niacin and its metabolites - nocotinamide, nicotinuric acid and N-methyl-2-pyridone-5-carboxamide - in human plasma by LC-MS/MS and its application to a human pharmacokinetic study. Biomedical Chromatography 2010; 24: 1059-1074.
10. Jain KS, Kathiravan MK, Somani RS and Shishoo CJ. The biology and chemistry of hyperlipedemia. Bioorganic & Medicinal Chemistry 2007; 15: 4674-4699.
11. LaRosa JC, Grundy SM, Waters DD, Shear C, Barter P, Fruchart J-C, Gotto AM, Greten H, Kastelein JJP, Shepherd J and Wenger NK. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. The New England Journal of Medicine 2005; 352: 1425-1435.
12. Levy DR and Pearson TA. Combination niacin and statin therapy in primary and secondary prevention of cardiovascular disease. Clinical Cardiology 2005; 28: 317-320.
13. Li L, Sun J, Sun Y and He Z. LC-ESI-MS determination of lovastatin in human plasma. Chromatographia 2008; 67: 621-625.
14. Patel BN, Sharma N, Sanyal M and Shrivastav PS. Simultaneous determination of simvastatin and simvastatin acid in human plasma by LC-MS/MS without polarity switch: application to a bioequivalence study. Journal of Separation Science 2008; 31: 301-313.
15. Pedersen TR, Faergeman O, Kastelein JJP, Olsson AG, Tikkanen MJ, Holme I, Larsen ML, Bendiksen FS, Lindahl C, Szarek M and Tsai J. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infraction: the IDEAL study: a randomize controlled trial. JAMA 2005; 294: 2437-2445.
16. Pieper JA. Understanding niacin formulations. The American Journal of Managed Care 2002; 8: S303-S314.
17. Tavintharan S and Kashyap ML. The benefits of niacin in atherosclerosis. Current Atherosclerosis Reports 2001; 3: 74-82.
18. Tobert JA. New developments in lipid-lowering therapy: the role of inhibitors of hydroxymethylglutaryl-coenzyme A reductase. Circulation 1987; 76: 534-538.
19. US DHHS, FDA, CDER. Guidance for Industry: Bioanalytical Method Validation. US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research and Center for Veterinary Medicine, 2001. Available at: .
20. Vickers S, Duncan CA, Chen IW, Rosegay A and Duggan DE. Metabolic disposition studies of simvastatin, a cholesterol lowering prodrug. Drug Metabolism and Disposition 1990a; 18: 138-145.
21. Vickers S, Duncan CA, Vyas KP, Kari PH, Arison SR, Prakash SR, Ramjit HG, Pitzenberger SM, Stokker G and Duggan DE. In vitro and in vivo bitransformation of simvastatin, an inhibitor of HMG-CoA reductase. Drug Metabolism and Disposition 1990b; 18: 476-483.
22. Windler E, Schoffauer M and Zyriax BC. The significance of low HDL-cholesterol levels in an ageing society at increased rish for cardiovascular disease. Diabetes and Vascular Disease Research 2007; 4: 136-142.